These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1080 related items for PubMed ID: 19922890

  • 1. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Dec; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Dec; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC.
    Can J Clin Pharmacol; 2001 Dec; 8(1):9-16. PubMed ID: 11283756
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
    Hobbs FD, Gensini G, Mancini GB, Manolis AJ, Bauer B, Böhler S, Genest J, Feldman R, Harvey P, Jenssen TG, Metcalfe M, da Silva PM, JEWEL Study Group.
    Int J Cardiol; 2006 Jun 16; 110(2):242-50. PubMed ID: 16338012
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L, Engelfriet P, Jacobs-van der Bruggen MA, Hoogenveen RT, Boshuizen HC, Verschuren MW.
    Eur J Cardiovasc Prev Rehabil; 2009 Jun 16; 16(3):371-6. PubMed ID: 19305351
    [Abstract] [Full Text] [Related]

  • 11. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Pharmacoeconomics; 2009 Jun 16; 27(3):221-30. PubMed ID: 19354342
    [Abstract] [Full Text] [Related]

  • 12. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH, Kim YD, Lim DS, Yoon MH, Ahn YK, On YK, Lee JW, Kim IJ, Park JB, Kim JJ, Chung WS, Yang JY, Seo HS, Shin EK, Kim HS, Korean Multicenter Amlodipine Study Investigators.
    Clin Ther; 2007 Sep 16; 29(9):1924-36. PubMed ID: 18035192
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan 16; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia.
    Bashir S, Sherwani MU, Shabbir I, Batool A.
    J Ayub Med Coll Abbottabad; 2011 Jan 16; 23(3):97-100. PubMed ID: 23272446
    [Abstract] [Full Text] [Related]

  • 18. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT trial investigators.
    Heart; 2008 Feb 16; 94(2):e4. PubMed ID: 17916665
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 16; 12(1):29-36. PubMed ID: 15703503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.